TScan Therapeutics, Inc. — Director's Dealing 2021

Jul 16, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: TScan Therapeutics, Inc. (TCRX)
CIK: 0001783328
Period of Report: 2021-07-15

Reporting Person: MacBeath Gavin (Chief Scientific Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Voting Common Stock	44767	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$1.97	2029-01-23	Voting Common Stock (35302)		Direct
Employee Stock Option (right to buy)	$2.46	2029-12-17	Voting Common Stock (52575)		Direct
Employee Stock Option (right to buy)	$5.82	2031-01-26	Voting Common Stock (166577)		Direct

Footnotes

F1: The shares originally subject to this option vested over 4 years of service following December 3, 2018, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. In addition, all of the shares subject to this option shall vest and become fully exercisable upon a Change of Control (as defined in the option agreement).

F2: The shares originally subject to this option vested over 4 years of service following December 5, 2019, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.

F3: The shares subject to this option vest over 4 years of service following January 25, 2021, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.